Improved diagnosis of SARS-CoV-2 by using nucleoprotein and spike protein fragment 2 in quantitative dual ELISA tests. (8th June 2021)

• Record Type: Journal Article
• Authors: De Marco Verissimo, Carolina; O'Brien, Carol; López Corrales, Jesús; Dorey, Amber; Cwiklinski, Krystyna; Lalor, Richard; Doyle, Jack M.; Field, Stephen; Masterson, Claire; Ribes Martinez, Eduardo; Hughes, Gerry; Bergin, Colm; Walshe, Kieran; McNicholas, Bairbre; Laffey, John G.; Dalton, John P.; Kerr, Colm; Doyle, Sean
• Is Part Of: Epidemiology and infection. Volume 149(2021)
• Publication Date: 2021-06-08
• Subjects: COVID-19, -- diagnosis, -- nucleocapsid protein, -- SARS-CoV-2, -- spike protein; Communicable diseases -- Periodicals; Epidemiology -- Periodicals; 614.4
• DOI: 10.1017/S0950268821001308
• Languages: English
• ISSNs: 0950-2688

Abstract

Abstract: The novel coronavirus, severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), is the causative agent of the 2020 worldwide coronavirus pandemic. Antibody testing is useful for diagnosing historic infections of a disease in a population. These tests are also a helpful epidemiological tool for predicting how the virus spreads in a community, relating antibody levels to immunity and for assessing herd immunity. In the present study, SARS-CoV-2 viral proteins were recombinantly produced and used to analyse serum from individuals previously exposed, or not, to SARS-CoV-2. The nucleocapsid (Npro) and spike subunit 2 (S2Frag) proteins were identified as highly immunogenic, although responses to the former were generally greater. These two proteins were used to develop two quantitative enzyme-linked immunosorbent assays (ELISAs) that when used in combination resulted in a highly reliable diagnostic test. Npro and S2Frag-ELISAs could detect at least 10% more true positive coronavirus disease-2019 (COVID-19) cases than the commercially available ARCHITECT test (Abbott). Moreover, our quantitative ELISAs also show that specific antibodies to SARS-CoV-2 proteins tend to wane rapidly even in patients who had developed severe disease. As antibody tests complement COVID-19 diagnosis and determine population-level surveillance during this pandemic, the alternative diagnostic we present in this study could play a role in controlling the spread of the virus.